Cutbacks Rise As Indian Pharma Tightens Control On Costs
Executive Summary
Leading Indian pharma firms are rationalizing operations and work forces to rein in costs and improve efficiency and profitability in a tough overall operating environment. Sun Pharma, which has declared an 'unwavering focus' on cost control, recently ended operations at two Indian clinical pharmacology units.
You may also be interested in...
Cipla-Alvotech Prime Emerging Markets Push With Humira Biosimilar Deal
Cipla has firmed up a commercialization deal with Alvotech for the Icelandic developer’s high-concentration version of AbbVie’s Humira, continuing to use the licensing approach to expand its biosimilar franchise in emerging markets.
Cipla Trims Staff At Indian Plant As It Eyes Costs
The rumor mill has it that Cipla has effected significant staff cuts at its Pithampur facility in India, as it keeps a sharp eye on costs and drives efficiencies at its manufacturing operations. But the company isn’t saying much except that it routinely conducts "performance-based reviews."
Sun To Trim US Manufacturing, Over 90 Jobs At Stake
Sun Pharma is consolidating its production activities in the US transferring operations out of its Cranbury site to the one in New Brunswick. Close to 100 jobs are expected to be affected.